Overview

• Biopharmaceutical firm's Q4 revenue grew 46% yr/yr

• Company completed acquisition of scPharmaceuticals, boosting cardiometabolic franchise

• Net loss reported for Q4 despite strong revenue growth

Outlook

• MannKind anticipates FDA decisions on Afrezza and Furoscix in 2026

• Company expects Nintedanib DPI Phase 1b data in 2H 2026

• MannKind sees ADA recommendations boosting Afrezza adoption

Result Drivers

• FUROSCIX SALES - Furoscix sales surged 91% in Q4 2025 following the acquisition of scPharmaceuticals, contributing significantly to revenue growth

• AFREZZA SALES - Afrezza sales increased 25% in Q4 2025, aided by its inclusion in ADA's 2026 Standards of Care, promoting broader adoption

• SC PHARMA ACQUISITION - Acquisition of scPharmaceuticals enhanced MannKind's cardiometabolic franchise, boosting overall revenue

Company press release: ID:nGNX1qDCYh

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for MannKind Corp is $10.00, about 185.7% above its February 25 closing price of $3.50

• The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 63 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)